Abstract: The present invention relates to a non-destructive method comprising placing a tissue sample on a porous matrix, centrifuging the tissue sample under a negative pressure, applying a vacuum on the tissue sample, and collecting extracted extracellular vesicles from the tissue sample. The method does not cause physical rupturing of the tissue sample and maintains integrity of the tissue sample for further histopathological analysis. Moreover, the invention also provides a method of inducing an immune response of a host by immune sensitization using harvested extracellular vesicles.

Abstract: A crop prediction system performs various machine learning operations to predict crop production and to identify a set of farming operations that, if performed, optimize crop production. The crop prediction system uses crop prediction models trained using various machine learning operations based on geographic and agronomic information. Responsive to receiving a request from a grower, the crop prediction system can access information representation of a portion of land corresponding to the request, such as the location of the land and corresponding weather conditions and soil composition. The crop prediction system applies one or more crop prediction models to the access information to predict a crop production and identify an optimized set of farming operations for the grower to perform.

Abstract: Technologies for generating a graphical user interface (GUI) dashboard with a three-dimensional (3D) grid of unit cells are described. An anomaly statistic can be determined for a set of records. A subset of network address identifiers can be identified and sorted according to the anomaly statistic. The subset can have higher anomaly statistics than other network address identifiers. There can be a maximum number in the subset. The GUI dashboard is generated with unit cells organized by the subset of network address identifiers as rows, time intervals as columns, colors as a configurable anomaly score indicator, and a number of network access events as column heights. Each unit cell is a colored, 3D visual object representing a composite score of anomaly scores associated with zero or more network access events corresponding to the respective network address identifier at the respective time interval. The GUI dashboard is rendered on a display.

Abstract: Technologies for generating a set of models for each account, where each model is a fine-grained, unsupervised behavior model trained for each user to monitor and detect anomalous patterns are described. An unsupervised training pipeline can generate user models, each being associated with one of multiple accounts and is trained to detect an anomalous pattern using feature data associated with the one account. Each account is associated with at least one of a user, a machine, or a service. An inference pipeline can detect a first anomalous pattern in first data associated with a first account using a first user model. The inference pipeline can detect a second anomalous pattern in second data associated with a second account using a second user model.

Abstract: The present invention provides novel therapeutic applications of low dose naltrexone (LDN). Said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of Toll-like receptor 9 (TLR9), an innate immune receptor which elicits the production of inflammatory cytokines when agonised. Chronic inflammation and TLR9 overexpression are characteristics of a number of disorders, including certain cancers. Accordingly, the present invention provides novel uses of naltrexone in the treatment of a subject having a disorder characterised by TLR9 overexpression and/or overactivity of TLR9-mediated signalling. The present invention also provides novel uses of naltrexone in the supportive care of subject having a tumour/cancer, and methods of treating and providing supportive care to a subject, comprising the administration of naltrexone.

Abstract: Apparatuses, systems, and techniques for classifying a candidate uniform resource locator (URL) as malicious using a machine learning (ML) detection system. An integrated circuit is coupled to physical memory of a host device via a host interface. The integrated circuit hosts a hardware-accelerated security service to protect one or more computer programs executed by the host device. The security service extracts a set of features from data stored in the physical memory, the data being words in a candidate URL and numeric features of a URL structure of the candidate URL. The security service classifies, using the ML detection system, the candidate URL as malicious or benign using the set of features. The security service outputs an indication of a malicious URL responsive to the candidate URL being classified as malicious.

Abstract: Apparatuses, systems, and techniques for detecting that one or more computer programs executed by a host device are subject to malicious activity using a machine learning (ML) detection system. An integrated circuit is coupled to physical memory of a host device via a host interface. The integrated circuit hosts a hardware-accelerated security service to protect one or more computer programs executed by the host device. The security service extracts a set of features from data stored in the physical memory, the data being associated with the one or more computer programs. The security service determines, using the ML detection system, whether the one or more computer programs are subject to malicious activity based on the set of features. The security service outputs an indication of the malicious activity responsive to a determination that the one or more computer programs are subject to the malicious activity.

Abstract: Apparatuses, systems, and techniques for classifying one or more computer programs executed by a host device as being ransomware using a machine learning (ML) detection system. An integrated circuit is coupled to physical memory of a host device via a host interface. The integrated circuit hosts a hardware-accelerated security service to protect one or more computer programs executed by the host device. The security service obtains a series of snapshots of data stored in the physical memory and extracts a set of features from each snapshot of the series of snapshots, each snapshot representing the data at a point in time. The security service classifies a process of the one or more computer programs as ransomware or non-ransomware using the set of features and outputs an indication of ransomware responsive to the process being classified as ransomware.

Abstract: Apparatuses, systems, and techniques for classifying one or more candidate uniform resource locators (URLs) as having a domain generation algorithm (DGA) domain using a machine learning (ML) detection system. An integrated circuit is coupled to physical memory of a host device via a host interface. The integrated circuit hosts a hardware-accelerated security service to protect one or more computer programs executed by the host device. The security service extracts a set of features from data stored in the physical memory, the data being domain characters in one or more candidate URLs. The security service classifies, using the ML detection system, the one or more candidate URLs as having a DGA domain or a non-DGA domain using the set of features. The security service outputs an indication of a DGA malware responsive to the one or more candidate URLs being classified as having the DGA domain.

Abstract: The present invention provides novel therapeutic applications of low dose naltrexone (LDN). Said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of Toll-like receptor 9 (TLR9), an innate immune receptor which elicits the production of inflammatory cytokines when agonized. Chronic inflammation and TLR9 overexpression are characteristics of a number of disorders, including certain cancers. Accordingly, the present invention provides novel uses of naltrexone in the treatment of a subject having a disorder characterised by TLR9 overexpression and/or overactivity of TLR9-mediated signalling. The present invention also provides novel uses of naltrexone in the supportive care of subject having a tumour/cancer, and methods of treating and providing supportive care to a subject, comprising the administration of naltrexone.

Abstract: The present disclosure relates to methods treating a clinical condition associated with a neurodegenerative disease or locomotor dysfunction in a subject. In particular, methods include administering to the subject in need of such a treatment a therapeutically effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof, or a prodrug thereof, where X, Ra, Rb, R1, R2, R3, R4, and R5 are those defined herein.

Abstract: A method for securing a network by applying one or more artificial intelligence (AI) models in a computing environment with a computing speed selected as a function of a bandwidth of the network. The method includes receiving data at a node associated with the network, and identifying a suspected cyber adversarial event at the network. The method includes applying an AI model on the data in real-time to enrich the data with information that indicates behavior associated with an exploitation of the network, and analyzing the enriched data as part of a cyber workflow for an indication of a compromise associated with the exploitation of the network.

Abstract: A method for securing a network by applying one or more artificial intelligence (AI) models in a computing environment with a computing speed selected as a function of a bandwidth of the network. The method includes receiving data at a node associated with the network, and identifying a suspected cyber adversarial event at the network. The method includes applying an AI model on the data in real-time to enrich the data with information that indicates behavior associated with an exploitation of the network, and analyzing the enriched data as part of a cyber workflow for an indication of a compromise associated with the exploitation of the network.

Abstract: The present invention provides novel therapeutic applications of low dose naltrexone (LDN). Said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of Toll-like receptor 9 (TLR9), an innate immune receptor which elicits the production of inflammatory cytokines when agonised. Chronic inflammation and TLR9 overexpression are characteristics of a number of disorders, including certain cancers. Accordingly, the present invention provides novel uses of naltrexone in the treatment of a subject having a disorder characterised by TLR9 overexpression and/or overactivity of TLR9-mediated signalling. The present invention also provides novel uses of naltrexone in the supportive care of subject having a tumour/cancer, and methods of treating and providing supportive care to a subject, comprising the administration of naltrexone.

Abstract: The present invention provides novel therapeutic applications of low dose naltrexone (LDN). Said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of Toll-like receptor 9 (TLR9), an innate immune receptor which elicits the production of inflammatory cytokines when agonized. Chronic inflammation and TLR9 overexpression are characteristics of a number of disorders, including certain cancers. Accordingly, the present invention provides novel uses of naltrexone in the treatment of a subject having a disorder characterized by TLR9 overexpression and/or overactivity of TLR9-mediated signalling. The present invention also provides novel uses of naltrexone in the supportive care of subject having a tumor/cancer, and methods of treating and providing supportive care to a subject, comprising the administration of naltrexone.

Abstract: The present invention provides novel therapeutic applications of low dose naltrexone (LDN). Said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of Toll-like receptor 9 (TLR9), an innate immune receptor which elicits the production of inflammatory cytokines when agonized. Chronic inflammation and TLR9 overexpression are characteristics of a number of disorders, including certain cancers. Accordingly, the present invention provides novel uses of naltrexone in the treatment of a subject having a disorder characterised by TLR9 overexpression and/or overactivity of TLR9-mediated signalling. The present invention also provides novel uses of naltrexone in the supportive care of subject having a tumour/cancer, and methods of treating and providing supportive care to a subject, comprising the administration of naltrexone.

Abstract: The present invention relates to recombinant DNA which encodes the AgeI restriction endonuclease as well as AgeI methyltransferase, and production of AgeI restriction endonuclease from E. coli cells containing the recombinant DNA.